CBLIF and rheumatoid arthritis: All RA and SpA patients, which were responding to treatment, had no detectable anti-drug Ab levels versus nonresponder patients: 1 patient with anti-ADA Ab and 14 patients with anti-INF Ab (P < 0.0001).